Clinical Pharmacokinetics

, Volume 56, Issue 12, pp 1479–1490 | Cite as

Penetration of Vancomycin into the Cerebrospinal Fluid: A Systematic Review

  • Jessica E. BeachEmail author
  • Jerrold Perrott
  • Ricky D. Turgeon
  • Mary H. H. Ensom
Systematic Review



Infectious disease and pharmacokinetic textbooks indicate that vancomycin has poor penetration into the central nervous system due to its hydrophilic nature and high molecular weight. Recent literature suggests that penetration of vancomycin into cerebrospinal fluid (CSF) is higher than previously reported; therefore, we conducted a systematic review to assess the penetration of vancomycin into CSF.


We searched the MEDLINE, EMBASE, and CENTRAL electronic databases for English-language human studies evaluating serum and CSF concentrations of intravenous vancomycin.


In 13 identified studies, the CSF-to-serum ratio of vancomycin varied from 0.00 to 0.81. CSF penetration ranged 0.06–0.81 in patients with meningitis, 0.05–0.17 in ventriculitis, 0.00–0.36 in other infections, and 0–0.13 in patients without infection. Despite variable CSF penetration, 83% of patients with meningitis and 100% of patients with ventriculitis achieved clinical cure. No factor predicted vancomycin CSF penetration.


Contrary to prior belief, studies included in our review did not show universally low penetration of vancomycin into CSF. CSF vancomycin levels were variable and did not predict clinical cure.


Compliance with Ethical Standards


No sources of funding were used to assist in the preparation of this review.

Conflicts of interest

Jessica E. Beach, Jerrold Perrott, Ricky D. Turgeon, and Mary H.H. Ensom have no conflicts of interest to declare that are relevant to the content of this review.


  1. 1.
    Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42:S5–12.CrossRefPubMedGoogle Scholar
  2. 2.
    Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267–84.CrossRefPubMedGoogle Scholar
  3. 3.
    Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858–83.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42:S35–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Lutsar I, Mccracken GH, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis. 1998;27:1117–29.CrossRefPubMedGoogle Scholar
  6. 6.
    Gilbert DN, Chambers HF, Eliopoulos GM, Saag MS, Black D, Feedman DO, et al. The Sanford Guide to antimicrobial therapy 2014, 44th ed. Sperryville, USA: Antimicrobial Therapy Inc.; 2014. p. 86.Google Scholar
  7. 7.
    Katzung BG, Masters SB, Trevor AJ. Basic and clinical pharmacology, 11th ed. USA: McGraw-Hill; 2009. p. 786.Google Scholar
  8. 8.
    Rybak M, Lomaestro B, Rotschafer J, Moellering RJ, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infecious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82–98.CrossRefPubMedGoogle Scholar
  9. 9.
    Ahmed A, Jafri H, Lutsar I, McCoig CC, Trujillo M, Wubbel L, et al. Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother. 1999;43:876–81.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, et al. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK Statement. Clin Pharmacokinet. 2015;54:783–95.CrossRefPubMedGoogle Scholar
  11. 11.
    Pfausler B, Spiss H, Beer R, Kampfl A, Engelhard K, Schober M, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg. 2003;98:1040–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Shokouhi S, Darazam IA. Determination of vancomycin trough level in serum and cerebrospinal fluid of patients with acute community-acquired meningitis: a prospective study. J Infect. 2014;69:424–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Caricato A, Pennisi M, Macino A, Vigna G, Sandroni C, Arcangeli A, et al. Levels of vancomycin in the cerebral interstitial fluid after severe head injury. Intensive Care Med. 2006;32:325–8.CrossRefPubMedGoogle Scholar
  14. 14.
    LeRoux P, Howard MA, Winn HR. Vancomycin pharmacokinetics in hydrocephalic shunt prophylaxis and relationship to ventricular volume. Surg Neurol. 1990;34:366–72.CrossRefPubMedGoogle Scholar
  15. 15.
    Ricard J, Wolff M, Lacherade J, Mourvillier B, Hidri N, Chevrel G, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis. 2007;44:250–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Albanèse J, Leone M, Bruguerolle B, Ayem M-L, Lacarelle B, Martin C. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother. 2000;44:1356–8.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Geraci JE, Heilman FR, Nichols DR, Wellman WE, Ross GT. Some laboratory and clinical experiences with a new antibiotic vancomycin. Proc Staff Meet Mayo Clin. 1956;31:564–82.PubMedGoogle Scholar
  18. 18.
    Viladrich PF, Gudiol F, Linares J, Pallarits R, Sabate I, Rufi G, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother. 1991;35:2467–72.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Aouinti I, Charfi R, Trabelsi S, Gaies E, Salouage I, Jebabli N, et al. Vancomycin therapeutic drug monitoring in cerebrospinal fluid. Therapie. 2014;69:529–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Lonsdale DO, Udy AA, Roberts JA, Lipman J. Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations. J Neurosurg. 2012;118:297–301.CrossRefPubMedGoogle Scholar
  21. 21.
    Nolan C, Flanigan WJ, Rastogi SP, Brewer TE. Vancomycin penetration into CSF during treatment of patients recieving hemodialysis. South Med J. 1980;73:1333–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Kirby WMM, Divelbiss CL. Vancomycin: clinical and laboratory studies. In: Welch H, Marti-Ibanez F, editors. Antibiotics Annual 1956–1957. New York: Medical Encyclopedia Inc.; 1957.Google Scholar
  23. 23.
    Li X, Wu Y, Sun S, Mei S, Wang J, Wang Q, et al. Population pharmacokinetics of vancomycin in postoperative neurosurgical patients. J Pharm Sci. 2015;104:3960–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Marsot A, Boulamery A, Bruguerolle B, Simon N. Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2012;51:1–13.CrossRefPubMedGoogle Scholar
  25. 25.
    Agrawal A, Cincu R, Timothy J. Current concepts and approach to ventriculitis. Infect Dis Clin Pract. 2008;16:100–4.CrossRefGoogle Scholar
  26. 26.
    Ng K, Mabasa VH, Chow I, Ensom MHH. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults. Neurocrit Care. 2014;20:158–71.CrossRefPubMedGoogle Scholar
  27. 27.
    Ziai WC, Lewin JJ. Update in the diagnosis and mangement of central nervous system infections. Neurol Clin. 2008;26:427–68.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Jessica E. Beach
    • 1
    Email author
  • Jerrold Perrott
    • 1
    • 2
  • Ricky D. Turgeon
    • 3
  • Mary H. H. Ensom
    • 1
    • 4
  1. 1.Faculty of Pharmaceutical SciencesUniversity of British ColumbiaVancouverCanada
  2. 2.Vancouver General HospitalVancouverCanada
  3. 3.Department of Medicine (Division of Cardiology)University of AlbertaEdmontonCanada
  4. 4.Children’s and Women’s Health Centre of British ColumbiaVancouverCanada

Personalised recommendations